Privatlivspræferencer
Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
  • Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • ShortsalgSe hvilke børsnoterede selskaber der har offentliggjorte korte positioner
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

SenzaGen’s interim report January–September 2026 | Increased revenue and efficiency deliver a profitable quarter; acquisition expands future commercial opportunities

SENZASelskabsmeddelelse05.11.2026, 07.30
Download udgivelse

Message from the CEO

“SenzaGen continued to grow and reported its first positive quarterly operating profit (EBIT) of SEK 1.1 million in the third quarter. EBITDA was positive both for the quarter and for the first nine months of the year, reflecting the scalability of our business model and disciplined execution.

Following the end of the reporting period, we entered into an agreement to acquire Alcyomics, significantly expanding our commercial potential into a new and growing area of drug development where the shift toward non-animal methods is accelerating. In its most recent financial year, Alcyomics reported approximately SEK 19.5 million in revenue with an EBITDA margin of approximately 24 percent.*

The acquisition accelerates the execution of our 2030 Growth Plan and our progress toward long-term profitable growth and increased shareholder value.”

Peter Nählstedt, President and CEO

Q3 2026

  • Net sales totaled SEK 16.3 (15.2) million.
  • EBIT amounted to SEK 1.1 (-1.0) million.
  • Earnings per share were SEK 0.04 (-0.02).

1 January–30 September 2026

  • Net sales totaled SEK 46.5 (42.4) million.
  • EBIT amounted to SEK -3.1 (-7.6) million.
  • Earnings per share were SEK -0.09 (-0.24).
  • Cash and cash equivalents at 30 September amounted to SEK 32.8 (29.3) million.

Significant events during the quarter

  • No significant events have occurred after the end of the reporting period.

Significant events after the end of the period

  • SenzaGen entered into an agreement to acquire Alcyomics, a leading and profitable UK provider of non-animal immunotoxicology testing for drug development, including biological anti-cancer drugs. The acquisition is expected to accelerate the Group’s growth and profitability.
  • The Group’s subsidiary VitroScreen received an order worth SEK 2.8 million for efficacy testing from an existing customer, a leading global producer of active ingredients for the health and beauty industry.

20262025Change20262025Change2025
SEK MJul-SepJul-Sep%Jan-SepJan-Sep%Jan-Dec

 

 


Revenue16.315.2746.542.41058.0
GARD®11.010.5532.529.51041.9
Gross margin, %776611 pts71683 pts65
EBITDA3.20.9
3.3-2.0
-8.8
EBIT1.1-1.0
-3.1-7.6
-11.6
Earnings/loss per share, SEK0.04-0.02
-0.09-0.24
-0.39
Cash and cash equivalents32.829.3
32.829.3
26.8

Livestream presentation
SenzaGen is pleased to invite press and investors to a livestream presentation today today, November 5, at 10:00 CET. The presentation will be given by SenzaGen’s President and CEO Peter Nählstedt, followed by a Q&A session moderated by Rodney Alfvén, partner at Hallvarsson & Halvarsson.

The presentation will be held in English.

Time: Thursday, Nov 5, 10:00 CET

Webcast
If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions.
https://senzagen.events.inderes.com/q3-report-2026/register

Teleconference
If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.  
https://events.inderes.com/senzagen/q3-report-2026/dial-in

The presentation can also be viewed later on SenzaGen's website: https://senzagen.com/investors/presentations/

* UK GAAP.

Contacts


Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Tel: +46 46-275 62 00

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Tel: +46 46-275 62 00

About us


SenzaGen is a fast‑growing company in the field of non‑animal chemical safety testing. Through ground-breaking innovations that better reflect human biology, the company works toward its vision of advancing and protecting human health while replacing the use of animals in testing. With GLP‑certified laboratories in Sweden and Italy, SenzaGen is driving the shift toward safer and more ethically sustainable testing practices. At the center of the offering is the company’s unique GARD® platform, which combines genomics and machine learning to deliver highly reliable decision‑support data for assessing skin and respiratory sensitization. SenzaGen’s strategy combines commercial focus, regulatory progress, and innovation to support long‑term profitable growth. SenzaGen is headquartered in Lund, Sweden, with subsidiaries in Italy and the United States. For more information, visit www.senzagen.com. 

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser. 

This information is information that SenzaGen is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-11-05 07:30 CET.

Attachments


SenzaGen AB (publ) January September 2026 Interim Report